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Abstract: To investigate the effect of brinzolamide on diurnal fluctuations in the intraocular pressure (IOP) in patients on 
latanoprost ophthalmic solution prospectively was aimed. Eleven patients with primary open angle glaucoma were en-
rolled in this study. The subjects were admitted to the hospital and had their IOPs measured over 24 hours (10 AM, noon, 
2 PM, 4 PM, 6 PM, 8 PM, 10 PM, midnight, 3 AM, 6 AM, and 8AM). After topical administration of brinzolamide twice 
daily for 4-8 weeks for one eye, they were readmitted and again had their IOPs measured in the same manner as during 
the previous admission. The additional administration of brinzolamide significantly reduced IOP by 9.7±4.5% during 24-
hour, 9.5±4.7% during daytime, and 10.3±5.6% during nighttime, respectively. Brinzolamide exerts additive effects over 
24 hours in reducing IOP in patients with glaucoma who are receiving latanoprost ophthalmic solution. 
Keywords: Brinzolamide, additive effect, diurnal IOP changes, latanoprost, intraocular pressure. 
INTRODUCTION 
  Intraocular pressure (IOP)-lowering therapy is the most 
effective and established approach for treatment of glau-
coma. There are several options for IOP-lowering therapy: 
medication, laser therapy and surgical treatment, among 
which medication is often the first choice for its consistent 
efficacy and safety. In recent years, it has been thought that 
maintaining IOP within the normal range is not enough to 
achieve sufficiently low IOP and it is now required to reach 
individualized target IOP [1]. Thus, there is growing need for 
more potent drugs than conventional IOP-lowering therapies. 
  IOP is known to fluctuate during the day because of di-
urnal rhythms and it is important to maintain a target IOP 
throughout a day in order to prevent progression of glau-
coma [2, 3]. Latanoprost is widely used all over the world as 
a first-line medication for glaucoma as it has an excellent 
IOP-lowering effect over 24 hours and is associated with 
only mild adverse reactions [4]. Latanoprost alone, however, 
sometimes to fail to achieve sufficiently low IOP, leading 
many patients to use two or more ophthalmic anti-glaucoma 
solutions [1]. Particularly in Japan, since there are many pa-
tients with normal tension glaucoma (NTG) [5], topical ad-
ministration of latanoprost alone often fails to produce suffi-
cient IOP-lowering effects. 
  Brinzolamide is a carbonic anhydrase inhibitor that 
causes fewer local or systemic adverse reactions [6]. It exerts 
an excellent IOP-lowering effect by suppressing formation 
of aqueous humor [7]. It is also known to significantly lower 
IOP over 24 hours and considered as an adequate ophthalmic 
solution for control of IOP over 24 hours [6, 8]. In Japan,  
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however, brinzolamide is not approved as a first-line drug 
for glaucoma and in clinical settings, it is often used con-
comitantly with other ophthalmic solution such as latano-
prost. Nevertheless, there have been few studies that exam-
ined the IOP-lowering effect of brinzolamide, especially 
during nighttime [9], when it is concomitantly administered 
with other drugs. Therefore, we investigated the IOP-
lowering effect of brinzolamide over 24 hours in patients 
with glaucoma who had been receiving latanoprost ophthal-
mic solution and who additionally received brinzolamide in 
one of their eyes, and evaluated the efficacy of the additional 
administration of brinzolamide. 
SUBJECTS AND METHODS 
  This study was conducted in accordance with the Decla-
ration of Helsinki, having appropriate institutional review 
board approval and the patients' written informed consent. 
Subjects 
  We studied seven patients with primary open angle glau-
coma (POAG) and four patients with NTG who had been 
receiving latanoprost ophthalmic solution alone in both eyes 
for at least 4 weeks. Their mean age was 58.1 years ranging 
from 42 to 73 years, and there were 6 men and 5 women. 
Patients were excluded from the study if they had uveitis, 
corneal diseases that might interfere with IOP measurements, 
a history of intraocular surgery, including laser therapy, or 
an MD of -15 dB or worse on Humphrey visual field test 30-
2. Patients on steroids or oral carbonic anhydrase inhibitor, 
or those who were deemed inappropriate by the investigator 
were also excluded from the study. All eligible patients were 
enrolled in the study from October 2004 to September 2006. 
Study Protocol 
  All patients received latanoprost ophthalmic solution in 
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this period, we confirmed that patient compliance was good 
and no adverse reactions occurred in association with latano-
prost. While on latanoprost, the patients were admitted to the 
Department of Ophthalmology of Yamanashi Prefectural 
Central Hospital and had their IOPs measured over 24 hours 
(10 AM, noon, 2 PM, 4 PM, 6 PM, 8 PM, 10 PM, midnight, 
3 AM, 6 AM, and 8AM). Measurements of IOP were taken 
in the sitting position by ophthalmologists using a Goldmann 
applanation tonometer. After testing for diurnal fluctuations 
in IOP, one eye with the higher IOP at 10 AM, or the right 
eye if the IOPs at 10 AM were the same in both eyes, was 
selected for brinzolamide administration twice daily (7 AM 
and 7 PM). After confirming that the additional administra-
tion of brinzolamide caused no adverse reactions, the pa-
tients were readmitted to the Department of Ophthalmology 
of Yamanashi Prefectural Central Hospital at week 4-8 of 
brinzolamide treatment and again had their IOPs measured in 
the same manner as during the previous admission. During 
IOP measurements, the ophthalmologists were blinded as to 
which eye was treated with brinzolamide. 
Analyzed Parameters 
  The following data were analyzed in this study: mean 
IOP, maximum IOP, minimum IOP, and a range of fluctua-
tions in IOP in brinzolamide-treated eye and brinzolamide-
untreated eye, comparison of IOP values and percent reduc-
tion in IOPs at each measurement point before and after 
brinzolamide administration, comparison of IOP values and 
percent reduction in IOPs between brinzolamide-treated eye 
and brinzolamide-untreated eye, and comparison of percent 
reduction in IOPs between daytime (8 AM, 10 AM, noon, 2 
PM, 4 PM, 6 PM) and nighttime (8 PM, 10 PM, midnight, 3 
AM). 
Statistical Tests 
  Mann-Whitney U test or paired-t test were employed for 
statistical analysis and a statistically significant difference 
was defined as less than 5%. All data expressed as 
mean±SD. 
RESULTS 
Changes in Mean Daily IOP 
  In brinzolamide-treated eye, the mean 24-hour IOP was 
14.6±2.2 mm Hg before brinzolamide administration and 
was significantly reduced by 10.3% to 13.1±1.9 mm Hg after 
brinzolamide administration (p=0.001). In brinzolamide-
untreated eye, the mean IOP was 13.5±2.8 mm Hg and 
13.8±2.7 mm Hg, respectively, showing no significant 
changes. 
Maximum and Minimum IOPs and a Range of Fluctua-
tions in IOP 
  In brinzolamide-treated eye, the maximum IOP was 
17.2±2.9 mm Hg before brinzolamide administration and 
was significantly reduced to 15.6±2.2 mm Hg after brinzo-
lamide administration (P=0.02). The minimum IOP was 
11.6±2.0 mm Hg before brinzolamide administration and 
was significantly reduced to 10.3±1.9 mm Hg after brinzo-
lamide administration (P=0.04). The range of fluctuations in 
IOP was 5.4±1.6 mm Hg before brinzolamide administration 
and 5.4±1.4 mm Hg after brinzolamide administration, 
showing no significant differences. 
  In brinzolamide-untreated eye, the maximum IOP was 
15.7±3.3 mm Hg before brinzolamide administration and 
16.5±2.8 mm Hg after brinzolamide administration, showing 
no significant differences. Both the minimum IOP and the 
range of fluctuations in IOP also showed no significant dif-
ferences before and after brinzolamide administration: the 
minimum IOP was 11.3±2.4 mm Hg versus 11.4±2.3 mm Hg 
and the range of fluctuations in IOP was 4.7±1.7 mm Hg 
versus 5.2±1.0 mm Hg. 
Diurnal Fluctuations in IOP After Brinzolamide Admini-
stration 
  The additional administration of brinzolamide resulted in 
a greater reduction in IOP at all the measurement points 
compared to latanoprost alone. Significant reductions were 
observed at 0 PM, 4 PM, 0 AM, 3 AM, 6 AM, and 8 AM 
(Fig.  1a). On the other hand, there were no significant 
changes in IOP in brinzolamide-untreated eye at any meas-
urement points (Fig. 1b). The percent reductions in IOPs at 6 
PM and 6 AM, time points immediately before brinzolamide 
administration, were lower than those at measured times just 
after brinzolamide administration (Fig. 2). Comparison of 
IOP values over 24 hours between brinzolamide-treated and 
brinzolamide-untreated eyes showed that IOP in brinzola-
mide-treated eye was lower at all the measurement points 
and there were significant differences in IOP at all the meas-
urement points except for at 0 PM and 10 PM (Fig. 3). Com-
parison of the percent reduction in IOPs between daytime (8 
AM, 10 AM, 0 PM, 2 PM, 4 PM) and nighttime (8 PM, 10 
PM, 0 AM, 3 AM) showed no significant differences, with a 
mean of 9.5±4.7% and 10.3±5.6%, respectively. 
DISCUSSION 
  IOP-lowering therapy is the most effective approach for 
treatment of glaucoma, regardless of pattern of glaucoma. 
Though surgical treatment can drastically lower IOP, it may 
sometimes cause a serious complication. Laser therapy has 
an excellent safety profile but poor efficacy. For these rea-
sons, ophthalmic solutions are often used as a first choice 
treatment for glaucoma. While there are a growing number 
of therapeutic options for glaucoma, latanoprost is the most 
widely used drug nowadays. Latanoprost has a beneficial 
effect of lowering IOP over 24 hours and it causes fewer 
adverse reactions [4]. However, there are many patients who 
can not be fully treated with latanoprost alone. 
  It has been shown that while -blockers cause fewer local 
adverse reactions and are effective in lowering IOP during 
daytime, this IOP-lowering effect is impaired during night-
time [10-12]. Therefore, there has been a need for drugs that 
can lower IOP even at night in order to maintain lower IOP 
over 24 hours. Brinzolamide is a carbonic anhydrase inhibi-
tor that suppresses formation of aqueous humor [6, 13]. 
There have been some reports that it causes fewer local ad-
verse reactions and lowers IOP over 24 hours [6, 9]. As the 
IOP-lowering effect of latanoprost is mediated by the uveo-
scleral pathway, we expected that combination therapy with 
latanoprost and brinzolamide might produce IOP-lowering 
effect over 24 hours, including during nighttime. The results 
of the present study showed that brinzolamide further en-
hanced the IOP-lowering effect of latanoprost over 24 hours, 
suggesting a potential for IOP-lowering therapy with more  
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Fig. (1). Changes in IOP over 24 hours after brinzolamide administration. (a) Brinzolamide-treated eye. (b) Brinzolamide-untreated eye.  
*P<0.05, all data expressed as mean±SD. Open diamond: before brinzolamide administration, closed circle: after brinzolamide administration. Additive Effect of Brinzolamide on Diurnal IOP Change in Latanoprost-Treated Eyes  The Open Ophthalmology Journal, 2008, Volume 2    163 
   
 
Fig. (2). Percent reduction in IOPs over 24 hours after brinzolamide administration. All data expressed as mean±SD. 
 
Fig. (3). Difference in IOP between right and left eyes before and after brinzolamide administration. * P<0.05, all data expressed as 
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consistency. In Japan, there are many patients with NTG [5] 
and there is a need for controlling IOP in patients in less than 
fourteen mmHg. Among 11 patients in our study, while only 
2 patients achieved consistent IOP control of 13 mm Hg or 
lower with latanoprost, 6 patients (54.5%) achieved IOP con-
trol of 13 mm Hg or lower after the additional administration 
of brinzolamide. This suggests that these two drugs can 
maintain IOP at 13 mm Hg or lower in more than a half of 
the patients and that the combination therapy with latano-
prost and brinzolamide may be useful in treating NTG. 
  This additive effect of the two drugs may be explained by 
their difference in mechanism of lowering IOP: latanoprost 
by promoting uveoscleral aqueous outflow and brinzolamide 
by suppressing formation of aqueous humor. 
  The percent reduction in IOPs tended to decrease imme-
diately before brinzolamide administration, suggesting a 
need for adjusting time of administration of other ophthalmic 
solutions in order to achieve IOP-lowering effect over 24 
hours. No patients in the present study discontinued brinzo-
lamide administration due to drug-related adverse reactions. 
This suggests that brinzolamide may be an excellent oph-
thalmic solution that causes fewer adverse reactions. The 
additional administration of brinzolamide resulted in an av-
erage reduction in IOP of 10.3%, demonstrating an equiva-
lent effect to oral carbonic anhydrase inhibitors [7]. While 
long-term use of oral carbonic anhydrase inhibitors should 
be avoided due to severe systemic adverse reactions [14], 
brinzolamide is associated with a lower incidence of adverse 
reactions and maintains the IOP-lowering effect over 24 
hours, suggesting that brinzolamide may be effective in 
treating glaucoma. 
  This study has a limitation mentioned below. Since the 
number of participates in this study is relatively small, it is 
required to perform further study to confirm our results with 
much more sample size. It is much better if we can compare 
the difference in the diurnal change of IOP between brinzo-
lamide alone and a combination of latanoprost and brinzola-
mide. However, brinzolamide is approved to be used as a 
second line drug by the government. 
REFERENCES 
[1]  Whitson JT. Glaucoma: a review of adjunctive therapy and new 
management strategies. Expert Opin Pharmacother 2007; 8: 3237-
49. 
[2]  Liu JH, Kripke DF, Twa MD, et al. Twenty-four-hour pattern of 
intraocular pressure in young adults with moderate to severe myo-
pia. Invest Ophthalmol Vis Sci 2002; 43: 2351-5. 
[3]  Liu JH, Zhang X, Kripke DF. Weinreb RN. Twenty-four-hour 
intraocular pressure pattern associated with early glaucomatous 
changes. Invest Ophthalmol Vis Sci 2003; 44: 1586-90. 
[4]  Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Ef-
fect of timolol, latanoprost, and dorzolamide on circadian IOP in 
glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000; 
41: 2566-73. 
[5]  Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary 
open-angle glaucoma in Japanese: The Tajimi Study. Ophthalmol-
ogy 2004; 111: 1641-8. 
[6]  Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a 
new topical carbonic anhydrase inhibitor for primary open-angle 
glaucoma and ocular hypertension. Brinzolamide Primary Therapy 
Study Group. Am J Ophthalmol 1998; 126: 400-8. 
[7]  Sugrue MF. Pharmacological and ocular hypotensive properties of 
topical carbonic anhydrase inhibitors. Prog Retin Eye Res 2000; 
19: 87-112. 
[8]  Cvetkovic RS, Perry CM. Brinzolamide : a review of its use in the 
management of primary open-angle glaucoma and ocular hyperten-
sion. Drugs Aging 2003; 20: 919-47. 
[9]  Nakamoto K, Yasuda N. Effect of concomitant use of latanoprost 
and brinzolamide on 24-hour variation of IOP in normal-tension 
glaucoma. J Glaucoma 2007; 16: 352-7. 
[10]  Larsson LI, Konstas AG, Mylopoulos N, et al. Intraocular pressure 
over 24 hours after repeated administration of latanoprost 0.005% 
or timolol gel-forming solution 0.5% in patients with ocular hyper-
tension. Ophthalmology 2001; 108: 1439-44. 
[11]  Costagliola C, Parmeggiani F, Virgili G, et al. Circadian changes of 
intraocular pressure and ocular perfusion pressure after timolol or 
latanoprost in Caucasians with normal-tension glaucoma. Graefes 
Arch Clin Exp Ophthalmol 2007; 15: 15. 
[12]  Konstas AG, Mylopoulos N, Karabatsas CH, et al. Diurnal in-
traocular pressure reduction with latanoprost 0.005% compared to 
timolol maleate 0.5% as monotherapy in subjects with exfoliation 
glaucoma. Eye 2004; 18: 893-9. 
[13]  Ingram CJ, Brubaker RF. Effect of brinzolamide and dorzolamide 
on aqueous humor flow in human eyes. Am J Ophthalmol 1999; 
128: 292-6. 
[14]  Hoyng PF, van Beek LM. Pharmacological therapy for glaucoma: a 
review. Drugs 2000; 59: 411-34. 
 
 
Received: September 18, 2008  Revised: October 20, 2008  Accepted: October 28, 2008 
 
© Abe and Kashiwagi; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-
nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
 
 
 
 